On October 12, 2021 Prokarium, a biopharmaceutical company pioneering the oncology field of microbial immunotherapy, and Wacker Biotech reported that they had signed a contract for the manufacturing of Prokarium’s microbial novel immunotherapy for bladder cancer (Press release, Prokarium, OCT 12, 2021, View Source [SID1234591157]). Under the terms of the initial agreement, Wacker Biotech will ramp up GMP (Good Manufacturing Practice) production of Prokarium’s Salmonella-based immunotherapy at its biotech site in Amsterdam using its LIBATEC technology.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Preparations for the start of production, technology transfer and scale-up for a Phase 1 trial are already underway, as announced by the companies. "We are very pleased to work with Wacker Biotech given their deep expertise with live microbial products and GMP production," said Kristen Albright, PharmD, Prokarium’s Chief Executive Officer. "This marks an exciting milestone essential to progressing our lead microbial immunotherapy program into clinic."
As a CDMO (Contract Development and Manufacturing Organization), Wacker Biotech will use its LIBATEC technology platform for Live Microbial Products (LMPs) in the project. The company’s site in Amsterdam is a pioneer in the field of LMP production. "With our LIBATEC platform, Wacker Biotech offers its customers over 15 years’ experience in process development and manufacturing pharmaceutical’s that contain living microorganisms", said Jörg Lindemann, Managing Director of Wacker Biotech B.V. "The LIBATEC platform can be used for a wide range of Live Microbial Products and is perfectly suited to support Prokarium with their Salmonella-based immunotherapy."